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Abstract
The diagnosis of sporadic Creutzfeldt-Jakob disease (CJD) is based on typical clinical findings and is
supported by a positive 14-3-3 Western blot of cerebrospinal fluid. However, it is not clear whether
14-3-3 indicates general neuronal damage or is of pathophysiological relevance in CJD. The fact that the
14-3-3 isoform spectrum in cerebrospinal fluid does not correspond to that found in the brain points to a
regulated process. To investigate a possible role of 14-3-3 proteins in transmissible spongiform diseases,
we generated a 14-3-3gamma-deficient mutant mouse line by using a classical knockout strategy. The
anatomy and cage behavior of the mutant mice were normal. Western blot analyses of brain
homogenates revealed no changes in the protein expression of other 14-3-3 isoforms (epsilon, beta, zeta,
and eta). Proteomic analyses of mouse brains by two-dimensional differential gel electrophoresis
showed that several proteins, including growth hormone, 1-Cys peroxiredoxin, CCT-zeta,
glucose-6-phosphate isomerase, GRP170 precursor, and alpha-SNAP, were differentially expressed.
Mutant and wild-type mice were inoculated either intracerebrally or intraperitoneally with the Rocky
Mountain Laboratory strain of scrapie, but no differences were detected in the postinoculation survival
rates. These results indicate that 14-3-3gamma is unlikely to play a causal role in CJD and related
diseases.
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The diagnosis of sporadic Creutzfeldt-Jakob disease (CJD) is based on typical clinical findings and is
supported by a positive 14-3-3 Western blot of cerebrospinal fluid. However, it is not clear whether 14-3-3
indicates general neuronal damage or is of pathophysiological relevance in CJD. The fact that the 14-3-3
isoform spectrum in cerebrospinal fluid does not correspond to that found in the brain points to a regulated
process. To investigate a possible role of 14-3-3 proteins in transmissible spongiform diseases, we generated a
14-3-3-deficient mutant mouse line by using a classical knockout strategy. The anatomy and cage behavior of
the mutant mice were normal. Western blot analyses of brain homogenates revealed no changes in the protein
expression of other 14-3-3 isoforms (, , , and ). Proteomic analyses of mouse brains by two-dimensional
differential gel electrophoresis showed that several proteins, including growth hormone, 1-Cys peroxiredoxin,
CCT-zeta, glucose-6-phosphate isomerase, GRP170 precursor, and -SNAP, were differentially expressed.
Mutant and wild-type mice were inoculated either intracerebrally or intraperitoneally with the Rocky Moun-
tain Laboratory strain of scrapie, but no differences were detected in the postinoculation survival rates. These
results indicate that 14-3-3 is unlikely to play a causal role in CJD and related diseases.
14-3-3 proteins are a family of highly homologous, ubiqui-
tously expressed isoforms that are involved in a wide variety of
physiological processes, including neuronal development, apo-
ptosis, cell cycle control, and signal transduction. The extraor-
dinary large number of 14-3-3 binding partners—more than
100 have been reported—suggests a role of 14-3-3 isoforms as
general regulatory proteins (reviewed in references 1, 4, 14,
and 41). Mammals express seven distinct 14-3-3 isoforms (, ε,
, , , , and ) which comprise 1% of the total amount of
soluble brain protein (6). Proteins of the 14-3-3 family have
been suggested to play a role in several neurological disorders
as a degeneration marker as well as in the actual disease
process (13, 20, 25, 31, 46). In particular, in spinocerebellar
ataxia, which is a “protein-folding disease,” a pivotal role for
14-3-3 proteins has been discovered (10). In sporadic
Creutzfeldt-Jakob disease (CJD), another protein-folding dis-
ease, the diagnosis is based on clinical findings and can be
supported by a positive 14-3-3 Western blot of cerebrospinal
fluid (22). However, it is not clear whether there is a functional
relationship between 14-3-3 proteins and the pathogenesis of
spongiform encephalopathies.
To investigate a possible relationship, we generated a 14-3-
3-deficient mutant mouse line. We chose 14-3-3 because this
isoform is one of the most abundant isoforms in the brain (29)
and the most abundant isoform in the cerebrospinal fluid of
CJD patients (45). Knockout and control mice were inoculated
intraperitoneally and intracerebrally with the Rocky Mountain
Laboratory (RML) strain of scrapie to study a potential role of
14-3-3 in the pathogenesis of prion disease.
Since 14-3-3 knockout mice display no obvious alterations
in their phenotype, we characterized these mice in more detail.
We used Western blot analysis to search for differences in the
expression patterns of specific proteins that are involved in
vesicle trafficking, neuronal migration, and apoptosis and ap-
plied a proteomic approach to identify novel differentially ex-
pressed proteins.
MATERIALS AND METHODS
Generation of 14-3-3-deficient mice. The 14-3-3 cDNA was used to screen
a 129SV mouse genomic lambda FIXII library (Stratagene) at high stringency.
DNA of positive clones was isolated, subcloned into pBluescript (Stratagene),
and analyzed by sequencing. A 17.5-kb genomic clone was used to construct the
14-3-3 targeting vector (see Fig. 1).
The linearized DNA of the 14-3-3 targeting vector was electroporated into
embryonic stem cells (E14), colonies were selected with G418 and 1-2-deoxy-
2-fluoro--D-arabinofuranosyl-5-iodouracil (FIAU), and doubly resistant clones
were analyzed by Southern blotting (see Fig. 1). Clones containing a homolo-
gously recombined gene were expanded and injected into mouse blastocysts to
obtain highly chimeric mice that transmitted the mutation through the germ line.
This was confirmed by Southern blotting (genomic DNA) and immunoblotting
(brain extracts). Subsequently, genotyping was performed by PCR (see Fig. 2).
Western blot analysis. For Western blot analysis, whole mouse brain was
prepared, homogenized in phosphate-buffered saline (1 ml/0.1 g of tissue) con-
taining aprotinin (1 	g/ml), phenylmethylsulfonyl fluoride (0.2 mM) and leupep-
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tin (0.5 	g/ml), and sonicated for 30 s. After centrifugation at 20,000 
 g for 10
min at 4°C, the supernatant was retained and the protein concentration was
determined by the bicinchoninic acid assay (Pierce). Brain preparations (10 to 20
	g of total protein) were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) (23) and blotted to polyvinylidene difluoride mem-
branes (semidry) for 30 min at 48 mA. For Western blot detection, the mem-
branes were blocked for 30 min in Tris-buffered saline (TBS)–0.075% Tween 20
containing 5% dry milk and 5% goat serum and incubated with specific primary
antibodies (14-3-3-1005, 14-3-3-εct, 14-3-3-199, 14-3-3-1002, and 14-3-3-2
[45]; CDK5 [C-8], and p35 [C-19] from Santa Cruz; BAD and Bcl2 from R&D
Systems; Akt and pAkt from Cell Signaling; all others from Synaptic Systems)
diluted in blocking buffer, followed by the respective horseradish peroxidase-
conjugated secondary antibody. Immunoreactive proteins were visualized by
enhanced chemiluminescence (ECL Plus system; Amersham Biosciences); and
bands were quantified using Quantity One software (Bio-Rad).
Histological methods. Formalin-fixed brain tissue of 14-3-3-deficient and
wild-type mice was cut into 2-mm-thick tissue blocks, decontaminated in con-
centrated formic acid for 1 h, postfixed in 4% phosphate-buffered formalin by the
method of Brown et al. (8), and embedded in paraffin. Brain sections (2 	m
thick) were deparaffinized, rehydrated using xylene and a graded ethanol series,
and first stained with hematoxylin and eosin.
For immunohistochemistry, antigen activity was enhanced by microwave treat-
ment of sections for three 5-min intervals in 2 mM hydrochloric acid. Nonspecific
binding was blocked with I-Block (Tropix; Applied Biosystems). The sections
were then incubated for 90 min with the primary polyclonal antibody against the
14-3-3 isoform (14-3-3-1005; dilution, 1:1,000) at room temperature, followed
by a corresponding secondary alkaline phosphatase-conjugated antibody (goat
anti-rabbit antibody [Dako]; dilution, 1:50) for 45 min. After neurofuchsin stain-
ing, the slides were counterstained with Haemalaun solution (Merck).
2D-DIGE. First-dimension isoelectric focusing was performed with immobi-
lized pH 3 to 10 nonlinear gradient gels (24-cm Immobiline dry strips pH 3–10
NL; Amersham Biosciences). IPG strips were rehydrated for 24 h in 7 M urea–2
M thiourea–4% CHAPS–1% dithiothreitol (DTT)–0.4% IPG buffer pH 3–10
NL–0.002% bromophenol blue. Whole brain samples were dissolved in 3 vol-
umes of ice-cold acetone and precipitated overnight at 20°C. Proteins were
pelleted, air dried for 1 h, and lysed in 7 M urea–2 M thiourea–4% CHAPS–30
mM Tris-HCl (pH 8.1) for subsequent labeling. Insoluble material was removed
by centrifugation. The proteins were labeled, as specified by the manufacturer,
with fluorescent dyes specifically developed for the two-dimensional 2D differ-
ence gel electrophoresis system (2D-DIGE) (CyDyes Cy2, Cy3, and Cy5 [Am-
ersham Biosciences]). Labeled samples were cup-loaded near the anodic end,
and isoelectric focusing was carried out for a total of 56,000 Vh. After focusing,
the strips were equilibrated for two 25-min intervals in 6 M urea–125 mM
Tris-HCl (pH 7.85)–3% SDS–20 (vol/vol) glycerol; 1% DTT was added for the
first equilibrium step, and 4.2% iodoacetamide (IAA) was added for the second
equilibrium step. SDS-PAGE was performed with homogeneous 11% polyacryl-
amide gels (254 by 200 mm) by the method of Tastet et al. (37) at 20 W/gel. All
gels were run in triplicate and analyzed with DeCyder differential analysis soft-
ware (Amersham Biosciences). For subsequent mass spectrometry (MS), the
proteins were stained with colloidal Coomassie blue by the method of Neuhoff et
al. (28) and spots were excised manually.
Protein identification. Excised spots were subjected to manual or automatic
in-gel digestion without prior alkylation, as specified in the protocols supplied
with the ProTeam Digest system (Tecan). MS grade trypsin was purchased
from Promega. For the acquisition of peptide mass fingerprints (PMF) by
matrix-associated laser desorption-ionization–time-of-flight (MALDI-TOF)
MS, the peptides extracted from the gel plugs were applied to a prestructured
sample support (AnchorChip target; Bruker) coated with a thin layer of
-cyano-4-hydroxy-cinnamic acid (16). The target was inserted into a Bruker
Ultraflex TOF/TOF instrument (35) and subjected to an automated analysis
loop using external calibration. Database searches in the NCBInr protein
sequence database restricted to the taxonomy Mus musculus were performed
using the Mascot Software 2.0 from Matrix Science (30) with carboxamidom-
ethylation of cysteines and oxidation of methionines as variable modifica-
tions. The monoisotopic mass tolerance was set to 100 ppm, and one missed
cleavage was allowed. Samples not unambiguously identified by PMF were
analyzed manually by MS/MS using the LIFT technology of the Ultraflex
TOF/TOF instrument (35) to obtain sequence information for selected pep-
tides (peptide fragment fingerprint). Database searches using combined PMF
and MS/MS data sets were performed as described above, with the fragment
mass tolerance set to 0.7 Da.
Inoculations. Mice were inoculated intraperitoneally (i.p.) with brain homog-
enate containing 3 or 6 log 50% lethal dose (LD50) infectious units or intrace-
rebrally (i.c.) with brain homogenate containing 3 
 5 or 3 
 2 log LD50
infectious units of RML (passage 5) scrapie prions prepared as described pre-
viously (9). The mice were monitored every second day, and scrapie was diag-
nosed on the basis of standard clinical criteria. The mice were killed on the day
of onset of terminal clinical signs of scrapie. Numbers of infected control animals
were 1 / and 1 / at 3 
 5 log LD50 i.c., 4 / and 1 / at 3 
 2 log LD50
i.c., 3 / and 2 / at 6 log LD50 i.p., and 2 / at 3 log LD50 i.p. Numbers
of infected 14-3-3-deficient mice were 6 at 3 
 5 log LD50 i.c., 4 at 3 
 2 log
LD50 i.c., 2 at 6 log LD50 i.p., and 5 at 3 log LD50 i.p.
RESULTS
Targeting of the murine 14-3-3 gene. A 14-3-3-deficient
mutant mouse line was generated by a classical knockout strat-
egy. The replacement of a SpeI-SmaI genomic DNA fragment
representing bp 5849078 to 5853467 (GeneID 22682) by the
neomycin resistance cassette resulted in deletion of 14-3-3
exon 2 (bp 5849248 to 5849901) (Fig. 1), which codes for bp
198 to 852 of the 14-3-3 mRNA (NM_018871). This repre-
sents more than 88% of the 14-3-3 coding sequence. Southern
blot and/or PCR genotyping of offspring resulting from inter-
breeding of mice heterozygous for the 14-3-3 deletion (Fig.
2A and B) showed that the respective genotypes (wild type
/; heterozygous KO /; homozygous KO /) were
present at the expected 1:2:1 Mendelian frequency.
Expression of 14-3-3 isoforms. The deletion of 14-3-3 pro-
tein in the knockout mice was confirmed by Western blot
analysis of brain homogenates from /, /, and / mice
(Fig. 2C). By using a specific anti-14-3-3 antiserum, no band
was detected in the homozygous knockout animals. In het-
erozygous animals, 14-3-3 levels were reduced to 78% of
wild-type values. We also tested the expression levels of the ,
, ε, and  14-3-3 isoforms in whole-brain homogenates but
found no significant changes (Fig. 2C).
Immunohistochemical analyses failed to detect 14-3-3 la-
belling in brains of the 14-3-3-deficient mice (Fig. 3B). The
immunolabelling of wild-type mouse brains showed predomi-
nantly a neuronal cytoplasmatic staining. This can be seen, for
example, in the pyramidal cell bodies in the CA1 region of the
hippocampus (Fig. 3A).
Anatomy and cage behavior. Neither heterozygous animals
of the F1 generation nor homozygous knockout mice of the F2
generation showed obvious phenotypic alterations. Examina-
tion of knockout animals revealed no differences in the mor-
phology and histological characteristics of the cortex, cerebel-
lum, heart, lungs, digestive organs, liver, kidneys, muscles,
salivary glands, testis, skin, or lymphatic system. Cage behavior
and life span were normal compared to those of control ani-
mals (data not shown).
Inoculation with pathological prion protein. To examine if
there is a pathophysiological role of 14-3-3 in prion disease,
we infected mice with pathological prion protein. After i.c. or
i.p. inoculation of knockout and heterozygous or wild-type
control mice with 3 or 6 log LD50 (i.p.) or with 3 
 2 or 3 
 5
log LD50 (i.c.) of RML-infected brain homogenate, no signif-
icant trend for prolonged survival of 14-3-3-deficient mice
was observed (Fig. 4). Histological examination of brain sec-
tions of terminally ill knockout and control mice revealed no
differences in the lesion pattern (Fig. 5). As in uninfected
knockout and wild-type mice, no differences in the expression
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levels of the , , ε, and  14-3-3 isoforms were detected by
Western blot analysis (data not shown).
Candidate proteins. Since 14-3-3 knockout mice display
no obvious alterated phenotype, we characterized these
mice in more detail. To analyze the levels of proteins that
are reported to be binding partners of 14-3-3 proteins or to
participate in the same signaling pathways, Western blot
analyses were performed. We observed no significant up- or
downregulation of BAD, Bcl2, phosphorylated Akt (pAkt),
or total Akt, proteins involved in an apoptosis pathway.
CDK5 and p35, proteins important in neuronal migration,
were expressed at the same level as in the control brain
homogenate. Several proteins involved in vesicle trafficking
were quantified because 14-3-3 was reported to bind phos-
pholipids (29) and because 14-3-3 proteins are thought to be
localized to synaptic vesicles, where they may promote
Ca2-dependent exocytosis (18). In particular, SNAREs
(SNAP-25, syntaxin, and synaptobrevin), SNARE-associ-
ated and regulatory proteins (complexin, synaptophysin,
synaptotagmin, synaptojanin, synaptogyrin, Rab 3a, Rab-
GDI, synapsin, N-ethylmaleimide-sensitive factor [NSF],
and -dynamin), and -synuclein were examined. None of
FIG. 1. Scheme of the 14-3-3 knockout strategy. N, NotI; B, BamHI; Sm, SmaI; Sp, SpeI; Bg, BgIII; op, outside probe; NEO, neomycin
resistance gene; TK, thymidine kinase gene. By sequencing of restriction fragments from the mouse genomic lambda insert (14-3-3; GeneID,
22628), more than 88% of the 14-3-3 coding sequence was found to be located in the SpeI-SmaI fragment (bp 5849248 to 5849901). This 14-3-3
exon 2 (bp 5849248 to 5849901) (indicated by a black box), including flanking regions between the SpeI and SmaI sites, was replaced by a neomycin
resistance cassette in the targeting vector.
FIG. 2. (A) Southern blot of brain heart infusion-digested mouse genomic DNA, applying a 0.68-kb outside probe. Replacement of the genomic
4-kb SpeI-SmaI fragment results in a reduction of about 2 kb. (B) Genotyping by PCR. The 330-bp band is amplified by using two primers that
bind in the neomycin resistance cassette. By applying two primers binding to the 14-3-3 coding sequence, a PCR product of 648 bp is amplified.
(C) Western blots of mouse brain homogenates, using specific antisera against the 14-3-3 isoforms , ε, , , and .
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these proteins showed altered expression levels in 14-3-3-
deficient mice (data not shown).
Proteomic analysis. Since our candidate protein approach
did not reveal altered expression of the tested proteins, we next
applied a more systematic proteomic approach. Using 2D-
DIGE we investigated mixtures of total-brain homogenates
from seven 12-week-old female 14-3-3 knockout and wild-
type control animals. Proteins showing different expression
levels in the brain pool gels (Fig. 6A) were confirmed by 2D
PAGE analysis of brains from individual mice, excised manu-
ally, and identified by MS. The proteins we found to be differ-
entially expressed in the brains of 14-3-3 knockout mice are
listed in Table 1, and the corresponding spots are shown in Fig.
6B.
As demonstrated by the Western blots, 2D gels, and subse-
quent MS, our data verify the complete deletion of the 14-3-3
isoform in mutant mice (Fig. 6B, panel III). Additionally, we
were able to identify six proteins whose expression levels are
differentially regulated in mutant mice (Fig. 6B; Table 1):
growth hormone, the antioxidant protein 1-Cys peroxiredoxin,
the zeta subunit (CCT-zeta-1) of T-complex protein 1 (a chap-
erone mediating protein folding), glucose-6-phosphate isomer-
ase (a glycolytic enzyme that exhibits extracellular cytokine
activity as an autocrine motility factor), the 170-kDa glucose-
regulated protein GRP170 precursor (a molecular chaperone
located in the endoplasmic reticulum that is induced mainly by
glucose starvation and oxygen deprivation), and -SNAP (a
SNARE-associated cytosolic protein).
Discussion
In this paper we report on the generation and characteriza-
tion of a 14-3-3-deficient mutant mouse line. The 14-3-3 pro-
tein family is characterized by widespread expression and high
homology between isoforms and species. Seven mammalian
isoforms with different subcellular localisation and function are
known (2). 14-3-3 isoforms form homo- and heterodimers,
bind to phosphorylated and nonphosphorylated motifs of a
wide variety of target proteins, and are involved in diverse
functions such as cell cycle control, apoptosis, and signal trans-
duction (reviewed in references 2, 4, and 14). Recent reports
emphasize that 14-3-3 proteins play a major role in protein-
folding diseases (10, 46).
Our main reason for the generation of 14-3-3-deficient
mutant mice was to test the hypothesis that 14-3-3 proteins
play a pathophysiological role in prion diseases since the ap-
FIG. 3. 14-3-3 labeling of the cell bodies in CA1 hippocampus in a normal murine brain (A) and a 14-3-3-deficient murine brain (B).
FIG. 4. Kaplan-Meier survival curves of mice inoculated either i.c. or i.p. with RML strain at 3 
 2 or 3 log LD50, respectively.
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pearance of 14-3-3 protein in cerebrospinal fluid supports the
clinical diagnosis of CJD. By using isoform specific antisera, it
was demonstrated that one 14-3-3 isoform () also appears in
cerebrospinal fluid in other neurodegenerative diseases and
dementias. Quantification of the , , ε, and  isoforms can
therefore be used to differentiate these diseases (45).
In the context of a possible role of 14-3-3 in CJD, there
were no differences in the survival times between 14-3-3 mu-
tant mice and control mice after i.c. or i.p. inoculation of strain
RML. Since there was no significant increase in the expression
levels of 14-3-3 isoform ε, , , or  in noninoculated and
inoculated 14-3-3-deficient mice, a compensatory upregula-
tion of other 14-3-3 isoforms is unlikely. However, it is possible
that the endogenous levels of other 14-3-3 isoforms suffice to
compensate for 14-3-3 loss or that the changes in subcellular
localization account for compensation. In any case, our results
do not support the view of a direct involvement of 14-3-3 in
the pathogenesis of prion diseases. Rather, the 14-3-3 isoforms
found in cerebrospinal fluid of CJD patients and animals with
transmissible spongiform encephalopathies are more general
markers of neurodestruction. The question why the spectrum
of 14-3-3 isoforms in the brain differs from that observed in
cerebrospinal fluid remains open. The most abundant 14-3-3
isoform, 14-3-3, and its phosphorylated form (previously
called  [38]) appear to be absent from the cerebrospinal fluid
of patients with CJD (45), but 14-3-3  has been identified in
amyloid plaques from patients with CJD (32). A possible role
of 14-3-3 proteins has also been suggested in other neurode-
generative diseases. In Alzheimer’s disease, 14-3-3 proteins
were found in the neurofibrillary tangles (24), where they mod-
ulate the phosphorylation of tau protein (17). In Parkinson’s
disease and Lewy body disease, 14-3-3 ε, , and  isoforms were
found to bind to -synuclein (4, 20, 42). A possible pathophys-
iological role of 14-3-3 proteins has also been discussed for
Parkinson’s disease, where, due to the increased expression of
-synuclein and the concomitant binding of 14-3-3 proteins, a
reduction in the amount of free cytosolic antiapoptotic 14-3-3
protein appears to occur (46). In the polyglutamine disease
spinocerebellar ataxia 1, 14-3-3 isoforms colocalize in ubiq-
uitin-positive nuclear inclusions with ataxin-1. Recently, it was
demonstrated that 14-3-3 isoforms ε and  bind and stabilize
ataxin-1 and modulate its neurotoxicity, depending on the Akt-
mediated phosphorylation status of ataxin-1 (10). For spino-
cerebellar ataxia 1, a chaperone suppression of ataxin-1 aggre-
gation by HDJ/2HSDJ was shown (12), which represents the
first example of chaperone involvement in polyglutamine dis-
ease. In Huntington’s disease, perinuclear inclusions contain
proteasomal proteins, -synuclein, and 14-3-3 proteins in ad-
dition to Huntingtin protein (43). In amyotrophic lateral scle-
rosis, 14-3-3 was not only localized in neuronal aggregates but
also found in glial cytoplasmic inclusions (15, 19).
These data indicate that 14-3-3 proteins might act as cochap-
erones or adapter proteins and be involved in the generation or
stabilization of protein aggregates in a more general manner.
While our present data show that this putative role of 14-3-3
is not relevant in transmissible spongiform encephalopathies, it
may well be important in one or more of the other neurode-
generative diseases for which a link to 14-3-3 proteins has been
established. The mouse line described here is ideally suited for
use in experiments to examine this possibility in corresponding
mouse models of other neurodegenerative diseases—at least as
far as the 14-3-3 isoform is concerned.
FIG. 5. Hematoxylin-eosin staining of brain samples from terminally ill 14-3-3 knockout mice (A and C) and wild-type control mice (B and
D) after inoculation with pathological prion protein (3 log LD50 of RML). (C and D) CA4, CA3, and parts of CA1 region of the hippocampus
and the dentate gyrus; (A and B) brain stem at the level of the locus coeruleus with the fourth ventricle and cerebellar vermis.
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The fact that 14-3-3 knockout mice do not show any obvi-
ous phenotypic changes leads to the assumption that other
proteins have taken over the role of 14-3-3. To examine this
in more detail, we extended the characterization of 14-3-3
knockout mice by using a hypothesis driven and a proteomic
approach.
For a 14-3-3ε deletion mutant mouse, hippocampal defects
and thinning of the cortex were reported (39). Neuronal mi-
gration in these mice is defective. In addition, 14-3-3ε binds to
CDK5/p35 phosphorylated NUDEL, prevents its dephosphor-
ylation, and thus influences its subcellular localization (39).
14-3-3 was also found to bind NUDEL in yeast-two-hybrid
assays (39). If there is a real functional involvement of 14-3-3
in this process of neuronal migration, it could not be proven by
using our mutant mouse. It is possible that 14-3-3ε can replace
14-3-3 in this process. However this isoform was not upregu-
lated in our mutant mouse.
Since 14-3-3 is known to bind phospholipids (33) and 14-
3-3 proteins were implicated in exocytosis (7, 27), we analysed
key proteins involved in vesicle trafficking and fusion. We ob-
served no differences between 14-3-3-deficient and control
mice. We also examined proteins involved in apoptosis regu-
lation, including BAD, which is a binding partner of 14-3-3
(47). Again, no differences in protein expression levels were
observed.
Further information was obtained by a proteomic approach.
2D-DIGE analyses revealed several differentially expressed
proteins. Six of these proteins have now been identified by MS.
FIG. 6. (A) 2D PAGE of CyDye-labeled whole-brain proteins of pooled brains from seven 12-week-old female wild-type mice (red) and seven
14-3-3 knockout mice (green). (B) Boxes I to VII show areas with differentially expressed proteins that were picked and identified by MS. Arrows
indicate identified proteins (see Table 1). In boxes V and VII, arrows with dotted lines indicate differentially expressed proteins that are not yet
identified.
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Further detailed analyses of these proteins and the pathways in
which they are involved will have to be carried out to elucidate
why these proteins are differentially expressed in 14-3-3 de-
letion mutant mice.
However, for some of these differentially regulated proteins,
a functional link to 14-3-3 may exist. -SNAP, for example, is
required for intracellular membrane trafficking. It binds to
syntaxin and recruits NSF to SNARE complexes. Another pre-
synaptic protein which was reported to bind 14-3-3 is Rim1, a
brain-specific rab3a binding protein and modulator of SNARE
function and exocytosis (36). In Caenorhabditis elegans, Rim1/
UNC-10 probably acts to regulate the priming step of presyn-
aptic vesicle fusion by promoting conformational changes in
syntaxin (21). Also CCT zeta, another differentially expressed
protein, which is part of a molecular chaperone TCP1 complex,
has been reported to be involved in vesicular trafficking (11).
GRP170 precursor protein is located at the endoplasmic
reticulum (ER) and is induced by ER stresses that are caused
by the accumulation of unfolded or immature proteins in the
ER and the decelerated protein trafficking via the ER (34).
The  isoform of 14-3-3 proteins is the major isoform in the
Golgi complex and is implicated in secretion and protein traf-
ficking (reviewed in reference 2). 1-Cys peroxiredoxin, an an-
tioxidant protein, was also shown to be differentially regulated.
In 14-3-3 knockout mice, this peroxidase is shifted to a more
acidic pI that corresponds to overoxidation of the active-site
cysteine into cysteine sulfinic acid (44). The same was found in
heart cells of PKC- knockout mice (26). Interestingly, CCT
zeta was also differentially expressed in the hearts of these
mice (26).
Taken together, further characterization of 14-3-3 deletion
mutant mice under different experimental settings should lead
to a greater understanding of the cellular function of the 14-3-3
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